Helius Medical Technologies (NASDAQ:HSDT) Shares Up 4.8% – What’s Next?

Helius Medical Technologies, Inc. (NASDAQ:HSDT) rose 4.8% during trading on Monday . The company traded as high as $0.75 and last traded at $0.68. Approximately 913,740 shares were traded during trading, an increase of 222% from the average daily volume of 283,716 shares. The stock had previously closed at $0.65.

Analyst Ratings Changes

Separately, Maxim Group restated a “hold” rating on shares of Helius Medical Technologies in a research note on Wednesday, October 16th.

Helius Medical Technologies Price Performance

The stock has a 50-day moving average price of $0.61 and a 200-day moving average price of $0.68. The firm has a market capitalization of $3.17 million, a PE ratio of -0.14 and a beta of 1.47.

Hedge Funds Weigh In On Helius Medical Technologies

A hedge fund recently bought a new stake in Helius Medical Technologies stock. Armistice Capital LLC purchased a new stake in Helius Medical Technologies, Inc. (NASDAQ:HSDT) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 130,000 shares of the company’s stock, valued at approximately $127,000. Armistice Capital LLC owned approximately 4.39% of Helius Medical Technologies at the end of the most recent reporting period. Institutional investors own 18.63% of the company’s stock.

Helius Medical Technologies Company Profile

Helius Medical Technologies, Inc, a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise.